Mark Aguillard
Corporate Officer/Principal at DERMTECH, INC.
Net worth: 52 650 $ as of 2024-04-29
Profile
Mark Aguillard is currently the Chief Commercial Officer at DermTech, Inc. He was previously the Chief Commercial Officer at Epic Sciences, Inc. from 2021 to 2023.
Aguillard received an undergraduate degree from Texas Tech University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DERMTECH, INC.
0.26% | 2023-09-19 | 90,000 ( 0.26% ) | 52 650 $ | 2024-04-29 |
Mark Aguillard active positions
| Companies | Position | Start |
|---|---|---|
| DERMTECH, INC. | Corporate Officer/Principal | 2023-09-18 |
Former positions of Mark Aguillard
| Companies | Position | End |
|---|---|---|
Epic Sciences, Inc.
 Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 2023-08-31 |
Training of Mark Aguillard
| Texas Tech University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| DERMTECH, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Epic Sciences, Inc.
Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Mark Aguillard
